Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heidagenlecleucel
- Development stage
- Unknown
- Lead developer
- Heidelberg University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Heidagenlecleucel (Heidi-cel) is an autologous, third-generation chimeric antigen receptor (CAR) T-cell therapy targeting CD19. Developed by Heidelberg University Hospital, it is designed for the treatment of CD19-positive hematologic malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL). Unlike standard second-generation CAR-T therapies, heidagenlecleucel incorporates both CD28 and 4-1BB (CD137) costimulatory domains alongside the CD3-zeta signaling domain to enhance T-cell activation, expansion, and persistence. In Germany, the Paul-Ehrlich-Institut (PEI) granted a hospital exemption (Krankenhausausnahme) for heidagenlecleucel, allowing for its in-house manufacturing and clinical administration.
- Other names
- Heidi-celheidagen-lecleucel
Beyond the preview
Go deeper on heidagenlecleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heidagenlecleucel.